M. Alexander-miller, G. Leggatt, and J. Berzofsky, Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy., Proceedings of the National Academy of Sciences, vol.93, issue.9, pp.4102-4107, 1996.
DOI : 10.1073/pnas.93.9.4102

H. Benlalam, N. Labarriere, B. Linard, L. Derre, E. Diez et al., Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy, European Journal of Immunology, vol.158, issue.7, pp.2007-2115, 2001.
DOI : 10.1002/1521-4141(200107)31:7<2007::AID-IMMU2007>3.0.CO;2-S

M. Bodinier, M. Peyrat, C. Tournay, F. Davodeau, F. Romagne et al., Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding, Nat Med, vol.6, pp.707-710, 2000.

L. Gattinoni, D. Powell, . Jr, S. Rosenberg, and N. Restifo, Adoptive immunotherapy for cancer: building on success, Nature Reviews Immunology, vol.115, issue.5, pp.383-393, 2006.
DOI : 10.1038/nri1842

N. Gervois, F. Heuze, E. Diez, and F. Jotereau, Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: Cytotoxic activity and T cell receptor gene rearrangements, European Journal of Immunology, vol.1, issue.4, pp.825-831, 1990.
DOI : 10.1002/eji.1830200417

N. Gervois, N. Labarriere, L. Guiner, S. Pandolfino, M. Fonteneau et al., High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells, Clin Cancer Res, vol.6, pp.1459-1467, 2000.

C. Hinrichs, L. Gattinoni, and N. Restifo, Programming CD8+ T cells for effective immunotherapy, Current Opinion in Immunology, vol.18, issue.3, pp.363-370, 2006.
DOI : 10.1016/j.coi.2006.03.009

F. Jotereau, M. Pandolfino, D. Boudart, E. Diez, B. Dreno et al., High-Fold Expansion of Human Cytotoxic T-Lymphocytes Specific for Autologous Melanoma Cells for Use in Immunotherapy, Journal of Immunotherapy, vol.10, issue.6, pp.405-411, 1991.
DOI : 10.1097/00002371-199112000-00003

T. Jung, U. Schauer, C. Heusser, C. Neumann, and C. Rieger, Detection of intracellular cytokines by flow cytometry, Journal of Immunological Methods, vol.159, issue.1-2, pp.197-207, 1993.
DOI : 10.1016/0022-1759(93)90158-4

N. Labarriere, M. Pandolfino, N. Gervois, A. Khammari, M. Tessier et al., Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients, Cancer Immunology, Immunotherapy, vol.51, issue.10, pp.532-538, 2002.
DOI : 10.1007/s00262-002-0313-3

N. Labarriere, M. Pandolfino, D. Raingeard, L. Guiner, S. Diez et al., Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes, International Journal of Cancer, vol.18, issue.2, pp.209-215, 1998.
DOI : 10.1002/(SICI)1097-0215(19981005)78:2<209::AID-IJC15>3.0.CO;2-5

A. Mackensen, N. Meidenbauer, S. Vogl, M. Laumer, J. Berger et al., T Cells for the Treatment of Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.24, issue.31, pp.5060-5069, 2006.
DOI : 10.1200/JCO.2006.07.1100

S. Mandruzzato, E. Rossi, F. Bernardi, V. Tosello, B. Macino et al., Large and Dissimilar Repertoire of Melan-A/MART-1-Specific CTL in Metastatic Lesions and Blood of a Melanoma Patient, The Journal of Immunology, vol.169, issue.7, pp.4017-4024, 2002.
DOI : 10.4049/jimmunol.169.7.4017

N. Meidenbauer, J. Marienhagen, M. Laumer, S. Vogl, J. Heymann et al., Survival and Tumor Localization of Adoptively Transferred Melan-A-Specific T Cells in Melanoma Patients, The Journal of Immunology, vol.170, issue.4, pp.2161-2169, 2003.
DOI : 10.4049/jimmunol.170.4.2161

O. Menzel, M. Migliaccio, D. Goldstein, S. Dahoun, M. Delorenzi et al., Mechanisms Regulating the Proliferative Potential of Human CD8+ T Lymphocytes Overexpressing Telomerase, The Journal of Immunology, vol.177, issue.6, pp.3657-3668, 2006.
DOI : 10.4049/jimmunol.177.6.3657

J. Neudorfer, B. Schmidt, K. Huster, F. Anderl, M. Schiemann et al., Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens, Journal of Immunological Methods, vol.320, issue.1-2, pp.119-131, 2007.
DOI : 10.1016/j.jim.2007.01.001

P. Romero, N. Gervois, J. Schneider, P. Escobar, D. Valmori et al., Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma, J Immunol, vol.159, pp.2366-2374, 1997.

S. Topalian, L. Muul, D. Solomon, and S. Rosenberg, Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials, Journal of Immunological Methods, vol.102, issue.1, pp.127-141, 1987.
DOI : 10.1016/S0022-1759(87)80018-2

D. Valmori, V. Dutoit, D. Lienard, F. Lejeune, D. Speiser et al., Tetramer-Guided Analysis of TCR ??-Chain Usage Reveals a Large Repertoire of Melan-A-Specific CD8+ T Cells in Melanoma Patients, The Journal of Immunology, vol.165, issue.1, pp.533-538, 2000.
DOI : 10.4049/jimmunol.165.1.533

D. Valmori, J. Fonteneau, C. Lizana, N. Gervois, D. Lienard et al., Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues, J Immunol, vol.160, pp.1750-1758, 1998.

V. Vignard, B. Lemercier, A. Lim, M. Pandolfino, Y. Guilloux et al., Adoptive Transfer of Tumor-Reactive Melan-A-Specific CTL Clones in Melanoma Patients Is Followed by Increased Frequencies of Additional Melan-A-Specific T Cells, The Journal of Immunology, vol.175, issue.7, pp.4797-4805, 2005.
DOI : 10.4049/jimmunol.175.7.4797

C. Yee, J. Thompson, D. Byrd, S. Riddell, P. Roche et al., Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells, Proceedings of the National Academy of Sciences, vol.71, issue.2, pp.16168-16173, 2002.
DOI : 10.1002/(SICI)1097-0215(19970410)71:2<142::AID-IJC3>3.0.CO;2-0

H. Zeh, D. Perry-lalley, M. Dudley, S. Rosenberg, and J. Yang, High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy, J Immunol, vol.162, pp.989-994, 1999.